Drug data · shortage, price, volume

Scopolamine patch: listed 15 months as a shortage, and the generic benchmark price fell 69% since 2021

The FDA has listed this drug as short in the past. The pharmacy benchmark says the generic patch now costs $4.22 per item, against $15.24 in 2017. Availability and price are different measures, so this page shows both over time.

FDA shortage list, 2026-10-27NADAC, October 2026Medicaid SDUDinferred monthno data
  1. The patch was on the FDA list from September 2018 to November 2019, 15 months, and is not listed now.
  2. 62% of shortage listings since 2014 lasted as long as this one. The median lasts 21 months.
  3. A generic 1 mg patch costs pharmacies $4.22 per item on the NADAC benchmark in October 2026, 69% below its 2021 median.
  4. Medicaid paid for 38,531 patch prescriptions in Q4 2025, 68% more than in Q4 2021.

Not medical advice. This page reports public records about supply and pharmacy cost. Ask a pharmacist or prescriber about your own medication.

Three clocks on one timeline

Each lane uses the same monthly axis, so you can read across: when the FDA listed the patch, what pharmacies were paying, and how many Medicaid prescriptions were filled.

on the listinferred across a missing captureno capture or no price$ per itemprescriptionspreliminary quarter

Swipe the chart sideways to see all 10 years.

Three clocks: FDA shortage list, pharmacy acquisition cost and Medicaid prescriptionsShared monthly timeline. Top lane: months the topical was on the FDA shortage list. Middle lane: NADAC price per item by strength. Bottom lane: Medicaid prescriptions per quarter. 201820192020202120222023202420252026FDA shortage listtopical, by name2017-07 to 2017-11: on the list (observed)2018-09 to 2018-09: on the list (observed)2018-10 to 2018-11: on the list (inferred across a missing capture)2018-12 to 2019-01: on the list (observed)2019-02 to 2019-04: on the list (inferred across a missing capture)2019-05 to 2019-11: on the list (observed)2024-10 to 2025-08: no capture of the FDA list for these monthsfirst listed Oct 2016Pharmacy costNADAC, $ per itembold = 1 mg generic$0$10$20NADAC reported no price for this strength from 2018-03 to 2020-01$15.24 in 2017$4.22 nowMedicaid fillsprescriptions per quartertopical2017Q3: 4,823 prescriptions; unsuppressed state rows only2017Q4: 9,914 prescriptions; unsuppressed state rows only2018Q1: 10,471 prescriptions; unsuppressed state rows only2018Q2: 2,388 prescriptions; unsuppressed state rows only2018Q3: 294 prescriptions; unsuppressed state rows only2018Q4: 199 prescriptions; unsuppressed state rows only2019Q1: 161 prescriptions; unsuppressed state rows only2019Q2: 62 prescriptions; unsuppressed state rows only2019Q3: 7,497 prescriptions; unsuppressed state rows only2019Q4: 11,848 prescriptions; unsuppressed state rows only2020Q1: 14,821 prescriptions; unsuppressed state rows only2020Q2: 13,430 prescriptions; unsuppressed state rows only2020Q3: 15,785 prescriptions; unsuppressed state rows only2020Q4: 15,677 prescriptions; unsuppressed state rows only2021Q1: 17,786 prescriptions; unsuppressed state rows only2021Q2: 21,928 prescriptions; unsuppressed state rows only2021Q3: 22,990 prescriptions; unsuppressed state rows only2021Q4: 22,921 prescriptions; unsuppressed state rows only2022Q1: 23,975 prescriptions; unsuppressed state rows only2022Q2: 28,658 prescriptions; unsuppressed state rows only2022Q3: 28,113 prescriptions; unsuppressed state rows only2022Q4: 25,276 prescriptions; unsuppressed state rows only2023Q1: 28,049 prescriptions; unsuppressed state rows only2023Q2: 29,500 prescriptions; unsuppressed state rows only2023Q3: 28,657 prescriptions; unsuppressed state rows only2023Q4: 26,067 prescriptions; unsuppressed state rows only2024Q1: 27,462 prescriptions; unsuppressed state rows only2024Q2: 28,308 prescriptions; unsuppressed state rows only2024Q3: 29,858 prescriptions; unsuppressed state rows only2024Q4: 29,044 prescriptions; unsuppressed state rows only2025Q1: 33,045 prescriptions; unsuppressed state rows only2025Q2: 36,925 prescriptions; unsuppressed state rows only2025Q3: 39,750 prescriptions; unsuppressed state rows only2025Q4: 38,531 prescriptions; unsuppressed state rows only2026Q1: 35,374 prescriptions (latest quarter, preliminary: CMS may revise); unsuppressed state rows only40k0
Top: months the patch name was on the FDA list (Wayback captures of the FDA page; the current FDA record says posted 2025-11-03). Middle: NADAC per item, one line per strength. Where NADAC reported no price for a strength for more than two months, the line breaks and the gap is hatched: we do not bridge missing prices. Bottom: Medicaid prescriptions per quarter. Medicaid volume: 20,361 rows pulled for this drug, 10,515 (52%) suppressed by CMS for small cells and left out, never counted as zero, so every bar is a floor; state XX national rows excluded; the hatched latest quarter is preliminary. Fills also move with Medicaid enrollment, so a change is not by itself evidence of a shortage.

How long do shortages last?

Each step is a drop in the share of FDA shortage listings still running. The dot is this drug.

Share of FDA shortage listings still running after N months, with this drug marked0%25%50%75%100%024487296120months on the FDA listmedian 21 monthsthis listing (ended): 15 mo62% lasted this long
Kaplan-Meier on 397 listings, 2014 to 2026, by ingredient. 18 months have no capture and are bridged by inference. Every listing behind this curve, with the method and a dated correction, is in the shortage length dataset.

What a pharmacy pays per unit

NADAC is the average price retail pharmacies pay, per item.

Pharmacy acquisition cost per unit, brand against genericTopical 1 mg$4.22
NADAC prices this form per item. It is acquisition cost, not a retail price.

Which forms are short

FDA listing by dosage form
FormListed nowMonths listedFDA records (2026-10-27)
topicalNo (last listed November 2019)29 (1 records)

Price by strength

Topical: generic acquisition cost per item by strength
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
1 mg$4.22$13.54$15.242017-10-69%21-month gap in NADAC reporting28
Read the price with care. NADAC is a national survey average of retail pharmacy invoices. It is not a quote, not what any patient paid, and it excludes discounts and rebates. A flat or falling benchmark during a shortage means pharmacies' average invoice cost did not rise, not that every patient could find the drug at that price.
FDA caution. The FDA drug shortage list is updated as manufacturers report and should not be relied on for medical care. Ask a pharmacist or prescriber about supply.

Questions

Is Scopolamine patch still in shortage?

The patch is not on the FDA shortage list as of 2026-10-27. It was listed from September 2018 to November 2019. FDA says not to rely on the list for medical care; ask a pharmacist.

Did the shortage raise the pharmacy price?

Not in the benchmark. The NADAC survey average for a generic 1 mg patch is $4.22 per item in October 2026, 69% below its 2021 median. NADAC is a national average of retail pharmacy invoices, so it measures what pharmacies pay on average, not what any one patient was charged.

Did Medicaid fills fall during the shortage?

No. CMS State Drug Utilization Data shows 38,531 Medicaid-paid patch prescriptions in Q4 2025, 68% more than in Q4 2021 (22,921). Those counts are a floor because CMS suppresses small cells, they cover Medicaid only and move with Medicaid enrollment, and they count prescriptions that were filled, not demand that went unmet. A change in fills is not by itself evidence of a shortage.

If you are trying to pay for or find this drug

Run a pharmacy, discount card, telehealth or assistance service that helps people pay for medicines? Apply to be evaluated for a page like this one, or hold a disclosed featured slot. Inclusion is earned. A slot is labelled sponsored and never implies a medical endorsement. Building a product on this data? Licence the widget or the data feed.

Cite this page

Figures are calculated from U.S. federal sources (see Data terms below) and rebuilt from dated snapshots. Cite it as:

OmniRx, "Scopolamine patch: FDA shortage, NADAC acquisition cost and Medicaid utilization", data as of October 2026. https://omnirx.org/drugs/scopolamine-system-transdermal

Embed this chart

Free with attribution: paste this where you want the chart. It sizes itself to its content. A small "Powered by OmniRx" link stays in the widget; white-label licences remove it and add your own branding.

<iframe id="lx-drug-scopolamine-system-transdermal" src="https://omnirx.org/embed/drug-scopolamine-system-transdermal" width="100%" height="640" style="border:1px solid #e2e8f0;border-radius:10px" title="Scopolamine patch shortage and price timeline by omnirx.org" loading="lazy"></iframe>
<script>addEventListener('message',function(e){if(e.origin!=='https://omnirx.org')return;var d=e.data||{};if(d.type==='lx-height'&&d.slug==='drug-scopolamine-system-transdermal'){var f=document.getElementById('lx-'+d.slug);if(f)f.height=d.height;}});</script>

Sources

Data terms. Every source above is published by a U.S. federal agency (CMS or FDA). CMS's data site labels its datasets inconsistently: of the 14 NADAC years, 5 carry the "public domain" label and 9 the "U.S. government works" label; of the 14 State Drug Utilization Data years, 6 carry the "public domain" label and 8 the "U.S. government works" label. We record each dataset's label verbatim and cite the source for every figure. Figures on this page are OmniRx calculations from those datasets, not statements by CMS or FDA, and no agency endorses this page.